Medicines Patent Pool in new agreements to bring drugs to developing world

7 July 2016

The Medicines Patent Pool (MPP), the United Nations-backed health organization working to increase access to HIV, viral hepatitis C and tuberculosis treatments in poorer parts of the world, has signed a series of new generic manufacturing licences with Indian and Chinese drugmakers.

Aurobindo Pharma (BSE: 524804), Emcure, Hetero Labs, Laurus Labs, Lupin (BSE: 500257) and Zydus Cadila, all from India, and China’s Desano, have been signed up for total of nine new sub-licensing agreements to produce generic versions of key World Health Organization (WHO) priority HIV and hepatitis C treatments.

Greg Perry, MPP's executive director, said: “These new sub-licences will secure greater volumes of low-cost medicines for people living with HIV and hepatitis C in low and middle-income countries. We look forward to working with the companies to speed delivery of these treatments to those most in need of better medical options."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK